Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation (TMF-Allo)
Faecal Microbiota Transplantation for Prevention of Graft-versus-host Sisease After Allogeneic Stem Cell Transplantation for Haematological Malignancies
Sponsor: French Society of Hematology
This PHASE2 trial investigates Acute Leukemia in Remission and Chronic Lymphocytic Leukemia and is currently actively recruiting participants. French Society of Hematology leads this study, which shows 6 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Apr 2023 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2022 — Apr 2023 [monthly]
Not Yet Recruiting PHASE2
▶ Show 1 earlier version
-
Sep 2021 — Nov 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- French Society of Hematology
- Ministry of Health, France
- University Hospital, Clermont-Ferrand
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amiens, France , Angers, France , Besançon, France , Clermont-Ferrand, France , Grenoble, France , Lille, France , Limoges, France , Lyon, France , Nancy, France , Nantes, France and 7 more locations